Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vivoryon Therapeutics has announced promising results from its Phase 2b study of varoglutamstat, showing significant improvement in kidney function, particularly among diabetic patients. The drug demonstrated an excellent safety profile and may offer a new treatment approach for diabetic kidney disease and other kidney disorders. The company plans further studies to confirm these effects.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.